Literature DB >> 9436706

Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle.

B Gartner1, C Moreno, A Marinaro, J Remohí, C Simón, A Pellicer.   

Abstract

A case of successful pregnancy in an in-vitro fertilization cycle, in spite of an accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration, is reported. The patient underwent two intracytoplasmic sperm injection cycles with thawed epididymal spermatozoa, in which, due to a pharmacist's mistake, ovarian stimulation was carried out by a combination of long-acting gonadotrophin-releasing hormone agonist (leuprolide depot) and gonadotrophins. A successful singleton pregnancy was achieved after intrauterine embryo transfer with the birth of a healthy boy after 38 weeks. We describe the circumstances and results of this clinical case, as well as reviewing the literature.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9436706     DOI: 10.1093/humrep/12.11.2557

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

1.  Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles.

Authors:  Erhan Şimşek; Esra Bulgan Kılıçdağ; Pınar Çağlar Aytaç; Gonca Çoban; Seda Yüksel Şimşek; Tayfun Çok; Bülent Haydardedeoğlu
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-06-01

2.  No significant long-term complications from inadvertent exposure to gonadotropin-releasing hormone agonist during early pregnancy in mothers and offspring: a retrospective analysis.

Authors:  Huan Wu; Xiaoyan Xu; Cong Ma; Yiran Zhou; Shanai Pei; Hao Geng; Ye He; Qianhua Xu; Yuping Xu; Xiaojin He; Ping Zhou; Zhaolian Wei; Xiaofeng Xu; Yunxia Cao
Journal:  Reprod Biol Endocrinol       Date:  2021-03-20       Impact factor: 5.211

3.  GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial.

Authors:  Francesco M Fusi; Claudio M Brigante; Laura Zanga; Mario Mignini Renzini; Chiara Bosisio; Rubens Fadini
Journal:  Reprod Biol Endocrinol       Date:  2019-11-29       Impact factor: 5.211

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.